Citigroup Inc Vaxcyte, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Citigroup Inc holds 165,795 shares of PCVX stock, worth $17.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

165,795

Previous 144,867 14.45%

Holding current value

$17.5 Million

Previous $9.9 Million 26.52%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$60.06 - $78.77 $1.26 Million - $1.65 Million	20,928 Added 14.45%	165,795 $12.5 Million
Q1 2024 May 10, 2024	BUY	$59.79 - $81.05 $3.94 Million - $5.35 Million	65,955 Added 83.58%	144,867 $9.9 Million
Q4 2023 Feb 09, 2024	SELL	$45.35 - $63.41 $749,499 - $1.05 Million	-16,527 Reduced 17.32%	78,912 $4.96 Million
Q3 2023 Nov 09, 2023	BUY	$46.0 - $53.1 $773,536 - $892,929	16,816 Added 21.39%	95,439 $4.87 Million
Q2 2023 Aug 10, 2023	SELL	$34.66 - $54.07 $2.41 Million - $3.76 Million	-69,463 Reduced 46.91%	78,623 $3.93 Million
Q1 2023 May 11, 2023	BUY	$36.27 - $47.2 $1.06 Million - $1.38 Million	29,320 Added 24.69%	148,086 $5.55 Million
Q4 2022 Feb 09, 2023	SELL	$20.58 - $47.95 $754,730 - $1.76 Million	-36,673 Reduced 23.59%	118,766 $5.69 Million
Q3 2022 Nov 10, 2022	BUY	$21.69 - $28.53 $2.16 Million - $2.84 Million	99,373 Added 177.24%	155,439 $3.73 Million
Q2 2022 Aug 10, 2022	BUY	$17.68 - $26.58 $772,368 - $1.16 Million	43,686 Added 352.88%	56,066 $1.22 Million
Q1 2022 May 12, 2022	SELL	$17.46 - $26.36 $594,565 - $897,637	-34,053 Reduced 73.34%	12,380 $299,000
Q4 2021 Feb 10, 2022	BUY	$19.32 - $26.45 $408,791 - $559,655	21,159 Added 83.72%	46,433 $1.11 Million
Q3 2021 Nov 10, 2021	BUY	$20.26 - $26.97 $512,051 - $681,639	25,274 New	25,274 $641,000

Others Institutions Holding PCVX

# of Institutions

290

Shares Held

110M

Call Options Held

248K

Put Options Held

109K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account